ArticleBMC cancer2010
Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma.
Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Article
- Physiology of chemokines in the cancer microenvironment.American journal of physiology. Cell physiology · 2023Review
- Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment.Cancers · 2021Review
- Clinical Application of Cytokines in Cancer Immunotherapy.Drug design, development and therapy · 2021Review
- CCL18 in the Progression of Cancer.International journal of molecular sciences · 2020Review
- The CCL20-CCR6 Axis in Cancer Progression.International journal of molecular sciences · 2020Review
- Functional Role of Dendritic Cell Subsets in Cancer Progression and Clinical Implications.International journal of molecular sciences · 2020Review
- The role of immune infiltrates as prognostic biomarkers in patients with breast cancer.Cancer immunology, immunotherapy : CII · 2019Review
- Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.Oncotarget · 2017Article
- Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer.Journal for immunotherapy of cancer · 2017Article
- Dendritic Cells in Sepsis: Pathological Alterations and Therapeutic Implications.Journal of immunology research · 2017Review
- C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.Oncotarget · 2016Article
- [Research progress in kidney dendritic cells].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2015Review
- Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis.Oncoimmunology · 2015Article
- Mutations in BALB mitochondrial DNA induce CCL20 up-regulation promoting tumorigenic phenotypes.Mutation research · 2014Article
- CCL21 Cancer Immunotherapy.Cancers · 2014Article
- Immunosuppressive effect of renal cell carcinoma on phenotype and function of dendritic cells.International urology and nephrology · 2014Article
- The role of chemoattractant receptors in shaping the tumor microenvironment.BioMed research international · 2014Review
- Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer.Frontiers in immunology · 2013Review
- IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients.Oncoimmunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal cell carcinoma (RCC) represents one of the most immunoresponsive cancers. Antigen-specific vaccination with dendritic cells (DCs) in patients with metastatic RCC has been shown to induce cytotoxic T-cell responses associated with objective clinical responses. Thus, clinical trials utilizing DCs for immunotherapy of advanced RCCs appear to be promising; however, detailed analyses concerning the distribution and function of DC subsets in RCCs are lacking.
methodsWe characterized the distribution of the different immature and mature myeloid DC subsets in RCC tumour tissue and the corresponding normal kidney tissues. In further analyses, the expression of various chemokines and chemokine receptors controlling the migration of DC subsets was investigated.
resultsThe highest numbers of immature CD1a+ DCs were found within RCC tumour tissue. In contrast, the accumulation of mature CD83+/DC-LAMP+ DCs were restricted to the invasive margin of the RCCs. The mature DCs formed clusters with proliferating T-cells. Furthermore, a close association was observed between MIP-3α-producing tumour cells and immature CCR6+ DC recruitment to the tumour bed. Conversely, MIP-3β and SLC expression was only detected at the tumour border, where CCR7-expressing T-cells and mature DCs formed clusters.
conclusionIncreased numbers of immature DCs were observed within the tumour tissue of RCCs, whereas mature DCs were found in increased numbers at the tumour margin. Our results strongly implicate that the distribution of DC subsets is controlled by local lymphoid chemokine expression. Thus, increased expression of MIP-3α favours recruitment of immature DCs to the tumour bed, whereas de novo local expression of SLC and MIP-3β induces accumulation of mature DCs at the tumour margin forming clusters with proliferating T-cells reflecting a local anti-tumour immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.